Evidence map›Paper›PMID 40727479›Full record

ArticleFrontiers in oncology2025

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis.

Yanjing Guo, Jingjing Wu, Qianming Bai, Juefeng Wan, Qifeng Wang, Xinhong He, Xiaowei Zhang, Zhiguo Luo, Liju Xing, Xin Liu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanjing Guo *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jingjing Wu *Department of Multidisciplinary Oncology, Fuzhou First General Hospital Affiliated with Fujian Medical University, Fujian, China.
Qianming BaiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Juefeng WanDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Qifeng WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xinhong HeDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaowei ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhiguo LuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Liju XingDepartment of Oncology, Jiangyin Traditional Chinese Medicine Hospital, Jiangyin, China.
Xin LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A remarkable sustained partial response was achieved with the application of gefitinib after progression on multiple lines of therapy. The main adverse event of gefitinib treatment in this patient was a grade 2 rash. (Funded by the National Natural Science Foundation of China [Grant No. 82003061] and the Shanghai Sailing Program [20YF1408800] to Yanjing Guo, the Natural Science Foundation of Shanghai [Grant No. 24ZR1412800] to Xin Liu).

Indexed as

aggressive fibromatosisEGFR 19delgefitinibpartial responsetargeted therapy

Identifiers

PMID40727479
PMCPMC12301188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.